Helicobacter最新文献

{"title":"Machine learning models in predicting failure of Helicobacter pylori treatment: A two country validation study","authors":"Fang Jiang,&nbsp;Thomas K. L. Lui,&nbsp;Chengsheng Ju,&nbsp;Chuan-Guo Guo,&nbsp;Ka Shing Cheung,&nbsp;Wallis C. Y. Lau,&nbsp;Wai K. Leung","doi":"10.1111/hel.13051","DOIUrl":"10.1111/hel.13051","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The success rate of clarithromycin-containing <i>Helicobacter pylori</i> treatment had declined globally. This study aims to explore the role of different machine learning algorithms in predicting failure of <i>H. pylori</i> treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We included 84,609 adult patients who had received the first course of clarithromycin-containing triple therapy for <i>H. pylori</i> in Hong Kong from 2003 to 2013 as training set. Results were validated in patients who had received similar triple therapy with 27,736 Hong Kong patients between 2014 and 2017 (internal cohort); and 18,050 UK patients between 2012 and 2017 (external cohort). The performance of 11 available machine learning algorithms were used to predict the failure of triple therapy. The performance was determined by the area under receiver operating characteristic curve (AUC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The treatment failure rates in the training, internal and external validation cohort was 5.9%, 9.5%, and 6.1%, respectively. In the internal validation set, Extra-Tree (ET) Classifier had the best AUC (0.88; 95% CI, 0.87–0.88), sensitivity (79.6%; 95% CI, 79.0–80.2) and specificity (79.4%; 95% CI, 79.0–79.8). In the external validation set, ET Classifier also had the best AUC (0.85; 95% CI, 0.85–0.86), sensitivity (80.1%; 95% CI, 79.5–80.9), and specificity (80.2%; 95% CI, 78.8–81.3). Top features of importance used by ET Classifier in predicting treatment failure included time interval between antibiotic use and triple therapy (48.8%), age (29.1%) and triple therapy regime (6.28%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Machine learning algorithm, based on simple baseline clinical parameters, could help to identify patients at high risk of failure from clarithromycin-containing triple therapy for <i>H. pylori</i>.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.13051","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139587656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seroprevalence of Helicobacter pylori infection among schoolchildren in southern Taiwan—A 20-year longitudinal follow-up","authors":"Hsiao-Yu Lo,&nbsp;Yao-Jong Yang","doi":"10.1111/hel.13049","DOIUrl":"https://doi.org/10.1111/hel.13049","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Helicobacter pylori</i> infection is primarily acquired in childhood and can lead to peptic ulcer diseases and gastric cancer. The prevalence of <i>H. pylori</i> infection varies widely in different countries. The aim of this study was to explore the change of pediatric <i>H. pylori</i> seroprevalence in the past two decades and to investigate the risk factors for pediatric <i>H. pylori</i> seropositivity in southern Taiwan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This study enrolled children aged 7–12 years in Tainan City in 2018 and compared the result with our previous data in 1998, 2005, and 2010. Parents of the participants were invited to fill out questionnaires, including information of personal history, family history of peptic ulcer diseases, annual household income, and source of drinking water. Blood samples were analyzed for anti-<i>H. pylori</i> IgG by enzyme-linked immunosorbent assay.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 391, 629, 618, and 488 elementary school students in Tainan City were enrolled in 1998, 2005, 2010, and 2018, respectively. There was a significant decline in <i>H. pylori</i> seroprevalence from 9.2% in 1998, 7.8% in 2005, 6.2% in 2010 to 4.7% in 2018 (<i>p</i> &lt; 0.001). Neither gender difference nor age difference was found in <i>H. pylori</i> seropositivity in each year of enrollment. Low household income was significantly associated with pediatric <i>H. pylori</i> seropositivity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The seroprevalence of <i>H. pylori</i> infection among elementary schoolchildren has remarkably declined in southern Taiwan in the past two decades. Low household income was a risk factor for pediatric <i>H. pylori</i> seropositivity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139550245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Helicobacter pylori infection and inflammasomes","authors":"Huiling Zheng,&nbsp;Pengyan Xia,&nbsp;Weiwei Fu,&nbsp;Shigang Ding","doi":"10.1111/hel.13043","DOIUrl":"https://doi.org/10.1111/hel.13043","url":null,"abstract":"<p><i>Helicobacter pylori</i> (<i>H. pylori</i>) causes the most prevalent bacterial infection worldwide, and more than half of the world's population is infected with <i>H. pylori</i>. Classified as a group 1 carcinogen of gastric cancer, <i>H. pylori</i> infection causes the most common chronic gastritis, which is able to progress to chronic atrophic gastritis, dysplasia, and even gastric cancer. The inflammasomes are important cytosolic multiprotein complexes to coordinate the host defense against foreign microorganisms and control the inflammatory response. It is also well-known that inflammasome plays an important role in the occurrence of <i>H. pylori</i>-induced gastric inflammation. During infection and inflammation, the activation process of inflammasome is tightly regulated by host immune system. However, excessive activation of inflammasome is closely related to the production of excessive cytokines that cause the body injury and resulting in various inflammatory diseases. In this review, we elaborate the activation and assembly mechanisms of inflammasome, the structure of different inflammasome complexes, host factors in vivo and drugs in vitro that regulate inflammasome signaling during <i>H. pylori</i> infection, aiming to provide novel insights and strategies for identifying new therapeutic targets for the treatment of <i>H. pylori</i>-associated gastric mucosal diseases.</p>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139550298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vonoprazan and amoxicillin dual therapy for 14 days as the first-line treatment of Helicobacter pylori infection: A non-inferiority, randomized clinical trial","authors":"Yi Hu,&nbsp;Xiang-Hua Huang,&nbsp;Bo Zhou,&nbsp;Meng-Lan Liu,&nbsp;Ye-Fei Liu,&nbsp;Tao Yu,&nbsp;Ping Sun,&nbsp;Bin-Bin Tan,&nbsp;Yang Hu,&nbsp;Fei Cheng,&nbsp;Xiao-Lin Pan,&nbsp;Jun-Bo Hong,&nbsp;Xu Shu,&nbsp;Yin Zhu,&nbsp;Nong-Hua Lu","doi":"10.1111/hel.13045","DOIUrl":"10.1111/hel.13045","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>We previously optimized the duration and dose of vonoprazan and amoxicillin dual therapy in China. The efficacy of vonoprazan with b.i.d. amoxicillin in comparison with vonoprazan-containing quadruple therapy as the first-line treatment of <i>Helicobacter pylori</i> infection has not been adequately evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In a non-inferiority, randomized clinical trial, <i>H. pylori</i> infected and treatment-naïve patients were randomly assigned to receive 14 days of either vonoprazan dual (vonoprazan 20 mg and amoxicillin 1 g twice daily) or quadruple therapy (vonoprazan 20 mg + amoxicillin 1 g + furazolidone 100 mg + bismuth potassium citrate 600 mg twice daily). <i>H. pylori</i> status was confirmed using ¹³C-urea breath tests or fecal antigen test. The primary outcome was the <i>H. pylori</i> eradication rate following vonoprazan dual and quadruple therapy at 4–12 weeks. We also compared drug compliance to either regimen and documented their side effect.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 190 subjects were randomized. The eradication rate of vonoprazan dual and quadruple therapy were 87.4% and 92.6% (<i>p</i> = 0.23) by intention-to-treat analysis, respectively, and 96.5% and 97.7% (<i>p</i> = 0.63) by per-protocol analysis, respectively. The efficacy of vonoprazan dual therapy was non-inferior to vonoprazan-containing quadruple therapy in per-protocol analysis (<i>p</i> &lt; 0.001; difference: −1.2%; 90% confidence interval: −5.4% to 3.0%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Vonoprazan with b.i.d. amoxicillin for 14 days provided similar satisfactory efficacy with vonoprazan-containing quadruple therapy as a first-line <i>H. pylori</i> treatment in China.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139557422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paving the way for a non-antibiotic and microbiota friendly therapy for Helicobacter pylori: In vitro and in vivo performance of lipid nanoparticles","authors":"Catarina Leal Seabra,&nbsp;A. Sofia Pinho,&nbsp;Cláudia Nunes,&nbsp;Irina Amorim,&nbsp;Nicole Pedro,&nbsp;Patrícia Henriques,&nbsp;Cláudia Monteiro,&nbsp;Joana Gomes,&nbsp;Cláudia Machado,&nbsp;Fátima Gartner,&nbsp;Luísa Pereira,&nbsp;Salette Reis,&nbsp;Celso A. Reis,&nbsp;Eliette Touati,&nbsp;Inês C. Gonçalves,&nbsp;Paula Parreira,&nbsp;M. Cristina L. Martins","doi":"10.1111/hel.13050","DOIUrl":"https://doi.org/10.1111/hel.13050","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The World Health Organization has identified <i>Helicobacter pylori</i>, a Gram-negative bacterium responsible for several gastric disorders, as one of the pathogenic bacteria that requires newer non-antibiotic approaches for its management. We previously demonstrated that nanostructured lipid carriers (NLC) loaded with docosahexaenoic acid (DHA-NLC) have excellent in vitro performance against <i>H. pylori</i>.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>NLC were tested against different <i>H. pylori</i> strains and bacteria representative from human gut microbiota. For <i>H. pylori</i>, resistance development and membrane permeability assays were also performed. In vivo efficacy studies were done using an <i>H. pylori</i>-infected mouse model. Microbiome analysis (16S rRNA sequencing analysis) was performed on mice feces before and after DHA-NLC treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>NLC specifically killed different <i>H. pylori</i> strains by membrane disruption without inducing bacterial resistance. In vivo studies demonstrated that DHA-NLC (2 mg/mL containing 50 μM of DHA) reduced 90%–95% of the <i>H. pylori</i> burden and eradicated infection in 50% of the animals when treatment was administrated ad libitum for 14 days. No significant differences were found between the administration procedure (ad libitum vs oral gavage). Also, increasing the DHA-NLC concentration to 4 and 8 mg/mL did not translate into an improvement in antibacterial performance. Notably, gut microbiome analysis showed no alterations, highlighting the safety to the gut microbiota. Finally, no histopathological changes were reported (stomach/liver sections).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Overall, our results emphasize DHA-NLC as a promising approach for <i>H. pylori</i> infection management, since they can effectively reduce the <i>H. pylori</i> burden without affecting gut microbiota and, in opposition to antibiotics, without anticipating the development of resistance to this treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139550247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clarifying varied Helicobacter pylori eradication therapies: A comprehensive review","authors":"Xiaoqi Wu,&nbsp;Miao Duan,&nbsp;Qingzhou Kong,&nbsp;Shuyan Zeng,&nbsp;Leiqi Xu,&nbsp;Yueyue Li,&nbsp;Xiaoyun Yang,&nbsp;Xiuli Zuo","doi":"10.1111/hel.13048","DOIUrl":"https://doi.org/10.1111/hel.13048","url":null,"abstract":"<p>Current global variations exist in <i>Helicobacter pylori</i> (<i>H</i>. <i>pylori</i>) eradication regimens. Triple therapy (TT), bismuth quadruple therapy (BQT), and high-dose dual therapy (HDDT) currently represent the predominant regimens. These regimens diverge in terms of treatment duration, the utilization of susceptibility testing, acid-inhibiting drug administration, and patient education. We conducted a comprehensive systematic literature review on these <i>H</i>. <i>pylori</i> treatment regimens. Our review aims to provide standardized treatment recommendations for <i>H</i>. <i>pylori</i>, reducing the risk of amalgamating findings from diverse eradication regimens. Recent research suggests that the optimal treatment duration for TT and BQT may be 14 and 10 days, respectively. Selecting the appropriate treatment duration for HDDT should rely on regional research evidence, and 14 days may be the optimal duration. The incorporation of susceptibility testing in TT is of paramount importance. In the case of BQT, the absence of susceptibility testing may be considered as an option, contingent upon cost and availability, and should be determined based on local antibiotic resistance patterns and the efficacy of empirical regimens. The type and dosage of acid-inhibiting drug would affect the efficacy of these regimens. Acid-inhibiting drugs should be selected and applied reasonably according to the population and therapies. Adequate patient education plays a pivotal role in the eradication of <i>H</i>. <i>pylori</i>. In regions with accessible local research evidence, the 10-day empirical BQT regimen may be considered a preferred choice for <i>H</i>. <i>pylori</i> eradication.</p>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139550259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concentration-dependent effect of amoxicillin against clinical strains of Helicobacter pylori","authors":"Z. Kaouah,&nbsp;J. Buyck,&nbsp;M. Pichon,&nbsp;C. Burucoa,&nbsp;L. Prouvensier,&nbsp;J. Moreau,&nbsp;S. Marchand,&nbsp;N. Gregoire,&nbsp;J. Cremniter","doi":"10.1111/hel.13044","DOIUrl":"https://doi.org/10.1111/hel.13044","url":null,"abstract":"","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139550248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric Helicobacter pylori infection does not contribute to extraoral halitosis and its eradication cannot achieve substantial reduction of halitosis","authors":"Ying Chen,&nbsp;Xiao Xian Qian","doi":"10.1111/hel.13047","DOIUrl":"https://doi.org/10.1111/hel.13047","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Some researchers have suggested that <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection is attributed to extraoral halitosis. However, this viewpoint is increasingly challenged by clinical practice. This study was conducted with the aim of investigating changes of extraoral halitosis before and after <i>H. pylori</i> eradication.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Data of patients who had <i>H. pylori</i> infection and extraoral halitosis were retrospectively collected. <i>H. pylori</i> infection was diagnosed by positive ¹³C urea breath test (UBT). Extraoral halitosis was diagnosed by organoleptic score (OLS) ≥2 in nose breath. A 14-day bismuth-based quadruple therapy was administered for <i>H. pylori</i> eradication. Extraoral halitosis was examined before eradication (T1), on the first day after eradication (T2), 1 month after eradication (T3), and 3 months after eradication (T4). Eradication effect was checked by UBT at T3.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 100 patients were included. Eradication was successful in 74 out of 100 (74%) patients (success group) and failed in 26 out of 100 (26%) patients (failure group). 32 out of 74 (43.24%) patients in success group and 10 out of 26 (38.46%) patients in failure group had reduced halitosis at T2, 9 out of 74 (12.16%) patients in success group and 2 out 26 (7.69%) patients in failure group had relapsed halitosis at T3, and 23 out of 74 (31.08%) patients in success group and 8 out of 26 (30.77%) patients in failure group had relapsed halitosis at T4, without significant difference between groups at any time (<i>p</i> = 0.918, <i>p</i> = 0.808, and <i>p</i> = 0.808 respectively).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p><i>Helicobacter pylori</i> infection does not contribute to extraoral halitosis. <i>H. pylori</i> eradication can achieve sustained but slight reduction of extraoral halitosis, probably due to its antibiotic effects on the gut microbiota rather than <i>H. pylori</i>.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139550246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of map-like redness development after eradication therapy for Helicobacter pylori infection","authors":"Sho Matsumoto,&nbsp;Mitsushige Sugimoto,&nbsp;Masakatsu Fukuzawa,&nbsp;Nana Uesugi,&nbsp;Eri Iwata,&nbsp;Yasuyuki Kagawa,&nbsp;Akira Madarame,&nbsp;Yohei Koyama,&nbsp;Takashi Morise,&nbsp;Kumiko Uchida,&nbsp;Hayato Yamaguchi,&nbsp;Shin Kono,&nbsp;Sakiko Naito,&nbsp;Takashi Kawai,&nbsp;Takao Itoi","doi":"10.1111/hel.13046","DOIUrl":"https://doi.org/10.1111/hel.13046","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Map-like redness is a newly identified endoscopic risk factor for gastric cancer in patients who received <i>Helicobacter pylori</i> eradication therapy. However, the incidence rate of map-like redness in patients who received eradication, and the risk factors for the development of map-like redness remain unclear. We hence aimed to investigate the incidence rate of map-like redness at 1-year post <i>H. pylori</i> eradication, and evaluated its associations with map-like redness and gastric cancer in relation with gastric condition.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Endoscopic severity of gastritis and map-like redness were retrospectively evaluated according to the Kyoto Classification of Gastritis in patients who had undergone endoscopy before and after <i>H. pylori</i> eradication therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The incidence rate of map-like redness for all 328 patients at a mean of 1.2 ± 0.6 years after eradication was 25.3% (95% confidence interval [CI]: 20.7%–30.4%). Patients who developed map-like redness were older, had more severe atrophy and intestinal metaplasia, a higher total score of the Kyoto Classification of Gastritis both before and after eradication, and a higher rate of gastric cancer history than patients who did not have map-like redness. On multivariate analysis, risk of map-like redness was increased in patients with intestinal metaplasia (odds ratio [OR]: 2.794, 95% CI: 1.155–6.757) and taking acid inhibitors (OR: 1.948, 95% CI: 1.070–3.547). Characteristics of <i>H. pylori</i>-positive patients with gastric cancer history were patients who were older (OR: 1.033, 95% CI: 1.001–1.066), taking acid inhibitors (OR: 4.456, 95% CI: 2.340–8.484), and with occurrence of map-like redness after eradication therapy (OR: 2.432, 95% CI: 1.264–4.679).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Map-like redness is observed in one fourth of patients at 1-year post eradication. Patients who developed map-like redness were found to have severe intestinal metaplasia and taking acid inhibitors, and hence such patients require increased attention at surveillance endoscopy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139550258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis","authors":"Ren-Chun Du,&nbsp;Yu-Xin Hu,&nbsp;Yaobin Ouyang,&nbsp;Li-Xiang Ling,&nbsp;Jing-Yuan Xu,&nbsp;Rina Sa,&nbsp;Xiao-Shun Liu,&nbsp;Jun-Bo Hong,&nbsp;Yin Zhu,&nbsp;Nong-Hua Lu,&nbsp;Yi Hu","doi":"10.1111/hel.13039","DOIUrl":"10.1111/hel.13039","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Recent clinical trials have evaluated the efficacy of vonoprazan-amoxicillin (VA) dual therapy as the first-line treatment for <i>Helicobacter pylori</i> infection in different regions with inconsistent results reported. In this systematic review and meta-analysis, we aimed to evaluate the efficacy of VA dual therapy compared to the currently recommended therapy for eradicating <i>H. pylori</i>.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A comprehensive search of the PubMed, Cochrane, and Embase databases was performed using the following search terms: (“<i>Helicobacter</i>” OR “<i>H. pylori</i>” OR “<i>Hp</i>”) AND (“vonoprazan” OR “potassium-competitive acid blocker” OR “P-CAB”) AND (“amoxicillin” OR “penicillin”) AND (“dual”). The primary outcome was to evaluate the eradication rate according to intention-to-treat and per-protocol analysis. The secondary outcomes were adverse events and compliance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 15 studies involving 4, 568 patients were included. The pooled eradication rate of VA dual therapy was 85.0% and 90.0% by intention-to-treat and per-protocol analysis, respectively. The adverse events rate and compliance of VA dual therapy were 17.5% and 96%, respectively. The efficacy of VA dual therapy was superior to proton pump inhibitors-based triple therapy (82.0% vs. 71.4%, <i>p</i> &lt; 0.01) but lower than vonoprazan-containing quadruple therapy (83.1% vs. 93.3%, <i>p</i> = 0.02). 7-day VA dual therapy showed lower eradication rates than 10-day (χ² = 24.09, <i>p &lt;</i> 0.01) and 14-day VA dual therapy (χ² = 11.87, <i>p &lt;</i> 0.01). The adverse events rate of VA dual therapy was lower than vonoprazan triple therapy (24.6% vs. 30.9%, <i>p</i> = 0.01) and bismuth-containing quadruple therapy (20.5% vs. 47.9%, <i>p</i> &lt; 0.01). No significant difference of compliance was observed between VA dual therapy and each subgroup.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>VA dual therapy, a novel regimen, showed high efficacy as the first-line treatment for <i>H. pylori</i> eradication, which should be optimized before application in different regions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138459703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}